Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback